India: Novartis fights on in Gleevec battle


Novartis has now appealed to the Supreme Court in a bid to overturn the rejection of its controversial patent for Gleevec. Archana Shanker of Anand and Anand discusses the issues raised by the case

The speculation seemed to have come to an end on June 26 2009 when the Intellectual Property Appellate Board (IPAB) gave its decision on the Novartis patent application directed to the beta crystalline version of imatinib mesylate (Gleevec), refusing the patent application. Novartis then filed a special leave petition (SLP) before the Supreme Court, which has issued notice to the respondents in the matter (Union of India and others) to decide the issue of maintainability.

The facts of the Novartis pre-grant oppositions are well known and this article is only an attempt to summarise the issues and the propositions of law that have been discussed in the judgment.

By way of background, Novartis AG, a Swiss pharmaceutical company, applied for patent number 1602/MAS/1998 claiming Swiss priority of July 18 1997 for an invention directed to a "beta crystalline form of imatinib mesylate". Cancer Patient Aid Association (CPAA), NATCO Pharma, CIPLA...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

.@MARQUES_IP also hosting workshops on coexistence agreements in Madrid 15/10 & Milan 16/10 http://t.co/lnKH83kuwa #trademarks

Oct 1 2014 02:22 ·  reply ·  retweet ·  favourite
ManagingIP profile

Some upcoming @MARQUES_IP events that might be of interest: Meet the Judges (London 15/10 & Vienna 17/10) http://t.co/lnKH83kuwa #trademark

Oct 1 2014 02:21 ·  reply ·  retweet ·  favourite
ManagingIP profile

BBC News - Counterfeit Xbox One makers charged in US and Australia http://t.co/wx2yNRclCP

Oct 1 2014 01:52 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


AIPPI Congress News 2014

Read this year's AIPPI Congress News - published daily by Managing IP direct from the AIPPI Annual Meeting in Toronto
null null null

October 2014

What we want from the Unitary Patent and UPC

The EU Unitary Patent and Unified Patent Court are set to launch within the next 18 months. In the first article of a year-long series, Emma Barraclough and James Nurton gauge the expectations and concerns of in-house counsel



Most read articles

Supplements